Abstract
The nonstenotic, nonfistulizing (or inflammatory) pattern of Crohn’s disease appears to be unstable in time and may evolve toward either the stenotic or the fistulizing pattern. We aimed to assess the course of the inflammatory disease and its relation to certain clinical characteristics. After a mean follow-up of 93 months, we evaluated 73 patients with an inflammatory pattern. The behavior trend and its relation to disease location, initial treatment, and need for corticosteroids, immunosuppressors, and surgical resection were analyzed. In 64% of the patients the inflammatory pattern did not change, while in 14 and 22% it evolved toward a stenotic and a fistulizing pattern, respectively. This change was mainly determined by the appearance of perianal disease (75%). The mean time to behavior evolution was 67 months. Most patients required corticosteroids (92%). Need for immunosuppressors (48%) and surgical resection (30%) was significantly greater (P&<0.05) among patients with a change in pattern than in those with persistent inflammatory disease. The inflammatory pattern of CD remains stable in about half of patients. The course of this pattern is not indolent, however, since the needs for immunosuppression and surgical resection during follow-up are considerable.
Similar content being viewed by others
References
De Dombal FT, Burton I, Goligher C: The early and late results of surgical treatment for Crohn’s disease. Br J Surg 11:805–816, 1971
Greenstein AJ, Lachman P, Sachar DB, et al.: Perforating and non-perforating indications for repeated operations in Crohn’s disease: Evidence for two clinical forms. Gut 29:588–592, 1988
Aeberhard P, Berchtold W, Riedtmann HJ, et al.: Surgical recurrence of perforating and nonperforating Crohn’s disease. Dis Colon Rectum 39:80–87, 1996
Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn’s disease: Report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15, 2000
Sachar DB, Andrews HA, Farmer RG, et al.: Proposed classification of patient subgroups in Crohn’s disease. Gastroenterol Int 5:141–154, 1992
Louis E, Collard A, Oger AF, et al.: Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777–782, 2001
Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Hepatol 170:2–6, 1989
Loftus EV, Schoenfeld P, Sandborn WJ: The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16:51–60, 2002
Tavarela F, Tomá J, Barros L, et al.: Clinical outcome of Crohn’s disease: Analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 7:306–313, 2001
Lichtenstein GR: Treatment of fistulizing Crohn’s disease. Gastroenterology 119:1132–1147, 2000
Hanauer SB, Sandborn W: Management of Crohn’s disease in adults. Am J Gastroenterol 96(3):635–643, 2001
Hinojosa J, Nos P, Ramírez JJ, et al.: Evolutive pattern in Crohn’s disease. A simplified index using clinical parameters predicts obstructive behaviour. Eur J Gastroenterol Hepatol 13:1–5, 2001
Nos P, Hinojosa J, Mora J, et al.: Validation of a simplified clinical index to predict evolving patterns in Crohn’s disease. Eur J Gastroenterol Hepatol 14:847–851, 2002
Vasiliauskas EA, Kam LY, Karp LC, et al.: Marker antibody expression stratifies Crohn’s disease with distinct clinical characteristics. Gut 47:1497–1496, 2000
Sans M, Tassies D, Pellise M, et al.: The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn’s disease. Aliment Pharmacol Ther 17:1039–1047, 2003
Cosnes J, Cattan S, Blain A, et al.: Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 8:244–250, 2002
Steinhart AH, Girgrah N, McLeod RS: Reliability of a Crohn’s disease clinical classification scheme based on disease behavior. Inflamm Bowel Dis 4:228–234, 1998
Pearson DC, May GR, Fick G, et al.: Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2:CD000067, 2000
Sandborn WJ: Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol 225(Suppl):92–99, 1998
Lamers CB, Griffioen G, Van Hogezand RA, et al.: Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol 230(Suppl):111–115, 1999
Nielsen OH, Vainer B, Rask-Madsen J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 15:1699–1708, 2001
Schwartz DA, Pemberton JH, Sandborn WJ: Diagnosis and treatment of perianal fistulas in Crohn’s disease. Ann Intern Med 135:906–918, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nos, P., Garrigues, V., Bastida, G. et al. Outcome of Patients with Nonstenotic, Nonfistulizing Crohn’s Disease. Dig Dis Sci 49, 1771–1776 (2004). https://doi.org/10.1007/s10620-004-9568-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-004-9568-1